Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 279 articles:
HTML format
Text format



Single Articles


    February 2018
  1. DE CARVALHO DOMINGUEZ SOUZA BF, Konig A, Rasche A, de Oliveira Carneiro I, et al
    A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses.
    J Hepatol. 2018 Feb 8. pii: S0168-8278(18)30079.
    PubMed     Text format     Abstract available


  2. PAPATHEODORIDIS GV, Sypsa V, Dalekos G, Yurdaydin C, et al
    8-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
    J Hepatol. 2018 Feb 7. pii: S0168-8278(18)30081.
    PubMed     Text format     Abstract available


    January 2018
  3. BERG T, Petersen J
    Predicting long-term response after stopping nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2018 Jan 31. pii: S0168-8278(18)30064.
    PubMed     Text format    


  4. LEMOINE M, Cooke GS
    The Egyptian hepatitis C programme: a model of HCV treatment intervention?
    J Hepatol. 2018 Jan 30. pii: S0168-8278(18)30068.
    PubMed     Text format    


  5. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [J Hepatol 68 (2018) 33-41].
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30013.
    PubMed     Text format    


  6. DA SILVA FILIPE A, Sreenu V, Hughes J, Aranday-Cortes E, et al
    Reply to: No effect of resistance-associated substitutions in patients with rare HCV subtypes following treatment with sofosbuvir-containing regimens.
    J Hepatol. 2018 Jan 12. pii: S0168-8278(18)30014.
    PubMed     Text format    


    December 2017
  7. SCHWARZINGER M, Rehm J, Mallet V
    "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 30. pii: S0168-8278(17)32539.
    PubMed     Text format    


  8. ALAVI M, Law MG, Dore GJ
    Reply to: "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 29. pii: S0168-8278(17)32538.
    PubMed     Text format    


  9. AMPUERO J, Jimeno C, Quiles R, Rosales JM, et al
    Impact of comorbidities on patients outcomes after interferon-free therapy-induced viral eradication in hepatitis.
    J Hepatol. 2017 Dec 27. pii: S0168-8278(17)32535.
    PubMed     Text format     Abstract available


  10. SCOTT N, Olafsson S, Gottfreethsson M, Tyrfingsson T, et al
    Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020.
    J Hepatol. 2017 Dec 20. pii: S0168-8278(17)32528.
    PubMed     Text format     Abstract available


  11. SODERHOLM J, Millbourn C, Busch K, Kovamees J, et al
    Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32485.
    PubMed     Text format     Abstract available


  12. HELLARD M, Scott N, Sacks Davis R, Pedrana A, et al
    Achieving hepatitis C elimination in Europe - to treatment scale up and beyond.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32486.
    PubMed     Text format    


  13. ASSELAH T, Hassanein T, Waked I, Mansouri A, et al
    Eliminating Hepatitis C within Low Income Countries - the need to cure Genotypes 4, 5, 6.
    J Hepatol. 2017 Dec 8. pii: S0168-8278(17)32482.
    PubMed     Text format     Abstract available


  14. ELSHARKAWY A, Raziky ME, Akel WE, Saeed KE, et al
    Planning and prioritizing direct acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32478.
    PubMed     Text format     Abstract available


  15. OVREHUS ALH, Krarup H, Birkemose I, Holm DK, et al
    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32475.
    PubMed     Text format    


  16. HEZODE C, Reau N, Svarovskaia ES, Doehle BP, et al
    Resistance Analysis in Patients with Genotype 1-6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Studies.
    J Hepatol. 2017 Dec 5. pii: S0168-8278(17)32476.
    PubMed     Text format     Abstract available


  17. ZOULIM F
    Inhibition of hepatitis B virus gene expression: a step towards functional cure.
    J Hepatol. 2017 Dec 4. pii: S0168-8278(17)32480.
    PubMed     Text format    


  18. BORST K, Frenz T, Spanier J, Tegtmeyer PK, et al
    Type I interferon receptor-signaling delays Kupffer cell replenishment during acute fulminant viral hepatitis.
    J Hepatol. 2017 Dec 2. pii: S0168-8278(17)32473.
    PubMed     Text format     Abstract available


    November 2017
  19. HARTL J, Ehlken H, Sebode M, Peiseler M, et al
    Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.
    J Hepatol. 2017 Nov 24. pii: S0168-8278(17)32445.
    PubMed     Text format     Abstract available


  20. KUBILIUN M, Patel SJ, Hur C, Dienstag JL, et al
    Early liver transplantation for alcoholic hepatitis: Ready for primetime?
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32452.
    PubMed     Text format    


  21. HUPA KL, Deterding K, Port K, Kimmann M, et al
    In Reply to: EASL RECOMMENDATIONS ON TREATMENT OF HEPATITIS C 2016 "Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?"
    J Hepatol. 2017 Nov 21. pii: S0168-8278(17)32443.
    PubMed     Text format    


  22. FORREST EH, Atkinson SR, Richardson P, Masson S, et al
    Application of Prognostic Scores in The Stopah Trial: Discriminant Function is no Longer the Optimal Scoring System in Alcoholic Hepatitis.
    J Hepatol. 2017 Nov 21. pii: S0168-8278(17)32440.
    PubMed     Text format     Abstract available


  23. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Text format     Abstract available


  24. TANG Y, Li H, Li J, Liu Y, et al
    Macrophage scavenger receptor 1 contributes to pathogenesis of fulminant hepatitis via neutrophil mediated complement activation.
    J Hepatol. 2017 Nov 14. pii: S0168-8278(17)32433.
    PubMed     Text format     Abstract available


  25. BUGGISCH P, Vermehren J, Mauss S, Gunther R, et al
    Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32431.
    PubMed     Text format     Abstract available


  26. OSSEMAN Q, Gallucci L, Au S, Cazenave C, et al
    The chaperone dynein LL1 mediates cytoplasmic transport of empty and mature hepatitis B virus capsids.
    J Hepatol. 2017 Nov 4. pii: S0168-8278(17)32424.
    PubMed     Text format     Abstract available


  27. CARRIERI MP, Protopopescu C, Marcellin F, Wittkop L, et al
    The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients.
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32406.
    PubMed     Text format    


  28. JANSSEN HLA, Brunetto MR, Kim YJ, Ferrari C, et al
    Safety, Efficacy and Pharmacodynamics of Vesatolimod (GS-9620) in Virally-Suppressed Patients with Chronic Hepatitis B.
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32408.
    PubMed     Text format     Abstract available


    October 2017
  29. MURCIA O, Carnicer F, Gomez-Escolar L, Miralles C, et al
    Direct antiviral agents against Hepatitis C virus: beneficial or harmful?
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32407.
    PubMed     Text format    


  30. POLLMANN J, Gotz JJ, Rupp D, Strauss O, et al
    Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32400.
    PubMed     Text format     Abstract available


  31. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Text format     Abstract available


  32. LONDONO MC, Forns X, Pascasio JM
    Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32385.
    PubMed     Text format    


  33. FRASER H, Martin NK, Brummer-Korvenkontio H, Carrieri P, et al
    Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32387.
    PubMed     Text format     Abstract available


  34. AZAB M, Shah S, Liu X, Ukken J, et al
    Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32390.
    PubMed     Text format    


  35. MUELLER H, Wildum S, Luangsay S, Walther J, et al
    A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393.
    PubMed     Text format     Abstract available


  36. BERG T, Petersen J
    Predicting long-term response after stopping nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32345.
    PubMed     Text format    


  37. YIP TC, Wong GL, Wong VW, Tse YK, et al
    Durability of Hepatitis B Surface Antigen Seroclearance in Untreated and Nucleos(t)ide Analogue-Treated Patients.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32332.
    PubMed     Text format     Abstract available


  38. HALFON P, Scholtes C, Izopet J, Larrat S, et al
    Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.
    J Hepatol. 2017 Oct 4. pii: S0168-8278(17)32333.
    PubMed     Text format     Abstract available


    September 2017
  39. LIEBER SR, Rice JP, Lucey MR, Bataller R, et al
    Controversies in Clinical Trials for Alcoholic Hepatitis.
    J Hepatol. 2017 Sep 28. pii: S0168-8278(17)32325.
    PubMed     Text format     Abstract available


  40. DI MAIO VC, Cento V, Aragri M, Paolucci S, et al
    Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for second-line regimens?
    J Hepatol. 2017 Sep 20. pii: S0168-8278(17)32288.
    PubMed     Text format    


  41. LIU X, Shen JJ, Jung Kim S, Lee YJ, et al
    Necessity of time series analysis and effects of direct-acting antivirals on HCV patients awaiting liver transplantation.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32290.
    PubMed     Text format    


  42. ESMAT G, Elbaz T, El Raziky M, Gomaa A, et al
    Effectiveness of ravidasvir plus sofosbuvir in interferon-naive and treated patients with chronic hepatitis c genotype-4.
    J Hepatol. 2017 Sep 18. pii: S0168-8278(17)32286.
    PubMed     Text format     Abstract available


  43. PRENNER S, Kulik L
    Reply to "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma".
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32283.
    PubMed     Text format    


  44. CARRIERI MP, Protopopescu C, Marcellin F, Rosellini S, et al
    Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.
    J Hepatol. 2017 Sep 12. pii: S0168-8278(17)32211.
    PubMed     Text format     Abstract available


  45. FANGAZIO S, Camatta D, Minh MT, Ceriani E, et al
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma.
    J Hepatol. 2017 Sep 7. pii: S0168-8278(17)32280.
    PubMed     Text format    


  46. IOANNOU GN, Green PK, Berry K
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273.
    PubMed     Text format     Abstract available


  47. KO HL, Lam TH, Ng H, Toh J, et al
    Identification of Slug and Sox7 as transcriptional repressors binding to the Hepatitis B Virus Core Promoter.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32276.
    PubMed     Text format     Abstract available


  48. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    PubMed     Text format    


  49. LEMON SM, Ott JJ, Van Damme P, Shouval D, et al
    Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32278.
    PubMed     Text format     Abstract available


  50. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    PubMed     Text format    


  51. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Premature ovarian senescence and high miscarriage rate impair fertility in women with hepatitis C virus infection.
    J Hepatol. 2017 Sep 4. pii: S0168-8278(17)32259.
    PubMed     Text format     Abstract available


  52. HUANG R, Liu Y, Wang J, Xia J, et al
    Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32270.
    PubMed     Text format    


  53. YIP TC, Chan HL, Wong VW, Wong GL, et al
    Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance".
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32266.
    PubMed     Text format    


    August 2017
  54. CALVARUSO V, Craxi A
    HBV recurrence after HCV clearance on DAAs: Sometimes They Come Back.
    J Hepatol. 2017 Aug 29. pii: S0168-8278(17)32256.
    PubMed     Text format    


  55. MALLET V, Bruneau J, Zuber J, Alanio C, et al
    Hepatitis E Virus-Induced Primary Cutaneous CD30(+) T cell Lymphoproliferative Disorder.
    J Hepatol. 2017 Aug 28. pii: S0168-8278(17)32250.
    PubMed     Text format     Abstract available


  56. KRAMER L, Laurain A, Sultanik P, Tremeaux P, et al
    "Empirical" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32251.
    PubMed     Text format    


  57. GARVEY P, Murphy N, Flanagan P, Brennan A, et al
    Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32249.
    PubMed     Text format     Abstract available


  58. MELE D, Mantovani S, Oliviero B, Grossi G, et al
    Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56bright NK cells.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32203.
    PubMed     Text format     Abstract available


  59. DONATO MF, Invernizzi F, Rossi G, Iavarone M, et al
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32200.
    PubMed     Text format    


  60. WAZIRY R, Hajarizadeh B, Grebely J, Amin J, et al
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199.
    PubMed     Text format     Abstract available


  61. DONG YANG J, Leise MD
    Reply to " Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
    J Hepatol. 2017 Aug 8. pii: S0168-8278(17)32201.
    PubMed     Text format    


  62. ZEUZEM S, Dvory-Sobol H, Brainard DM
    No Effect Of Resistance-Associated Substitutions In Patients With Rare HCV Subtypes Following Treatment With Sofosbuvir-Containing Regimens.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32191.
    PubMed     Text format    


  63. DA SILVA FILIPE A, Sreenu V, Hughes J, Aranday-Cortes E, et al
    Response to DAA Therapy in the NHS England Early Access Programme for Rare HCV Subtypes from Low and Middle Income Countries.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32195.
    PubMed     Text format    


    July 2017
  64. LAZARUS JV, Wiktor S, Colombo M, Thursz M, et al
    Micro-elimination - A path to global elimination of hepatitis C.
    J Hepatol. 2017 Jul 28. pii: S0168-8278(17)32141.
    PubMed     Text format    


  65. SUDA T, Shimakami T, Shirasaki T, Yamashita T, et al
    Reactivation of Hepatitis B Virus from an isolated Anti-HBc positive patient after eradication of Hepatitis C Virus with Direct-acting Antiviral Agents.
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32158.
    PubMed     Text format    


  66. LOK AS, Zoulim F, Dusheiko G, Ghany MG, et al
    Hepatitis B cure: From discovery to regulatory approval.
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32017.
    PubMed     Text format     Abstract available


  67. RAJORIYA N, Combet C, Zoulim F, Janssen HLA, et al
    How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualized approach?
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32154.
    PubMed     Text format     Abstract available


  68. DALTON HR, van Eijk JJJ, Cintas P, Madden RG, et al
    Hepatitis E Virus Infection and Acute Non-Traumatic Neurological Injury: A Prospective Multicentre Study.
    J Hepatol. 2017 Jul 19. pii: S0168-8278(17)32153.
    PubMed     Text format     Abstract available


  69. SAMJI H, Yu A, Kuo M, Alavi M, et al
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32133.
    PubMed     Text format     Abstract available


    June 2017

  70. Response to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C.
    J Hepatol. 2017 Jun 29. pii: S0168-8278(17)32129.
    PubMed     Text format    


  71. YIP TC, Chan HL, Wong VW, Tse YK, et al
    Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Jun 23. pii: S0168-8278(17)32092.
    PubMed     Text format     Abstract available


  72. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    PubMed     Text format    


  73. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Text format     Abstract available


  74. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    PubMed     Text format    


  75. NAGATA H, Nakagawa M, Asahina Y, Sato A, et al
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070.
    PubMed     Text format     Abstract available


  76. SUSSER S, Dietz J, Schlevogt B, Zuckerman E, et al
    Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
    J Hepatol. 2017 Jun 12. pii: S0168-8278(17)32069.
    PubMed     Text format     Abstract available


  77. DURIEZ M, Mandouri Y, Lekbaby B, Wang H, et al
    Alternative splicing of Hepatitis B virus: a novel virus/host interaction altering liver immunity.
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32065.
    PubMed     Text format     Abstract available


    May 2017
  78. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    PubMed     Text format     Abstract available


  79. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    PubMed     Text format    


  80. COLPITTS CC, Baumert TF
    SCARB1 variants and HCV infection: Host susceptibility is lost in translation.
    J Hepatol. 2017 May 3. pii: S0168-8278(17)30255.
    PubMed     Text format    


  81. WENDON, J, Cordoba J, Dhawan A, Larsen FS, et al
    EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure.
    J Hepatol. 2017;66:1047-1081.
    PubMed     Text format     Abstract available


  82. MRIDHA AR, Wree A, Robertson AAB, Yeh MM, et al
    NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    J Hepatol. 2017;66:1037-1046.
    PubMed     Text format     Abstract available


    April 2017
  83. BANKWITZ D, Doepke M, Hueging K, Weller R, et al
    Maturation of secreted HCV particles by incorporation of secreted apoE protects from antibodies by enhancing infectivity.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30251.
    PubMed     Text format     Abstract available


  84. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30249.
    PubMed     Text format     Abstract available


  85. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed     Text format    


  86. HALLAGER S, Ladelund S, Weis N
    Methodological considerations when calculating person time at risk for patients with chronic hepatitis C undergoing antiviral treatment.
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30218.
    PubMed     Text format    


  87. LOUVET A, Peck-Radosavljevic M
    Evidence for a role of genetics in alcoholic hepatitis: data from the STOPAH randomized controlled trial.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30210.
    PubMed     Text format    


  88. LENGGENHAGER D, Gouttenoire J, Malehmir M, Bawohl M, et al
    Visualization of hepatitis E virus RNA and proteins in the human liver.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30212.
    PubMed     Text format     Abstract available


  89. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


  90. THONS C, Senff T, Hydes TJ, Manser AR, et al
    HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30213.
    PubMed     Text format     Abstract available


  91. VAN SANTEN DK, Van Der Helm JJ, Del Amo J, Meyer L, et al
    Lack of decline in Hepatitis C Virus incidence among HIV-positive men who have sex with men during 1990-2014.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30209.
    PubMed     Text format     Abstract available


  92. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Reply to "Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030".
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30204.
    PubMed     Text format    


  93. DORE GJ, Grebely J
    Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30206.
    PubMed     Text format    


  94. TUMINO N, Casetti R, Fabbri G, Cimini E, et al
    In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30207.
    PubMed     Text format    


  95. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    PubMed     Text format     Abstract available


  96. LANGHANS B
    Reply to "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals".
    J Hepatol. 2017 Apr 9. pii: S0168-8278(17)30205.
    PubMed     Text format    


  97. SCHWARZINGER M, Baillot S, Yazdanpanah PY, Rehm PJ, et al
    Contribution of Alcohol Use Disorders on the Burden of Chronic Hepatitis C in France, 2008-2013: A Nationwide Retrospective Cohort Study.
    J Hepatol. 2017 Apr 7. pii: S0168-8278(17)30202.
    PubMed     Text format     Abstract available


  98. SHIRVANI-DASTGERDI E, Winer BY, Celia-Terrassa A, Kang Y, et al
    Selection of the highly replicative and partially multidrug resistant rtS78T polymerase mutation in two patients with chronic hepatitis B virus infection during tenofovir-entecavir combination therapy.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30198.
    PubMed     Text format     Abstract available


    March 2017
  99. WESTHAUS S, Deest M, Nguyen AT, Stanke F, et al
    Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.
    J Hepatol. 2017 Mar 28. pii: S0168-8278(17)30184.
    PubMed     Text format     Abstract available



  100. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
    J Hepatol. 2017 Mar 27. pii: S0168-8278(17)30185.
    PubMed     Text format     Abstract available


  101. WELZEL T, Bhardwaj N, Hedskog C, Chodavarapu K, et al
    Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses.
    J Hepatol. 2017 Mar 23. pii: S0168-8278(17)30148.
    PubMed     Text format     Abstract available


  102. MARTIN NK, Vickerman P, Hickman M
    How to eliminate HCV infection by antiviral treatment.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30142.
    PubMed     Text format    


  103. BRUNETTO M, Cornberg M, Chan HL
    How Good Is Hepatitis B Surface Antigen Kinetics Informing Strategy to Stop Antiviral Therapy?
    J Hepatol. 2017 Mar 15. pii: S0168-8278(17)30136.
    PubMed     Text format    


  104. MALLET V, Hamed K, Schwarzinger M
    Erratum to "Prognosis of patients with chronic hepatitis B in France (2008-2013): A nationwide, observational and hospital-based study".
    J Hepatol. 2017 Mar 8. pii: S0168-8278(17)30112.
    PubMed     Text format    


  105. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30126.
    PubMed     Text format     Abstract available


    February 2017
  106. PIROTH L, Wittkop L, Lacombe K, Rosenthal E, et al
    Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-coinfected patients - French ANRS CO13 HEPAVIH cohort.
    J Hepatol. 2017 Feb 21. pii: S0168-8278(17)30107.
    PubMed     Text format     Abstract available


  107. RAMOS-CASALS M, Zignego AL, Ferri C, Brito-Zeron P, et al
    Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.
    J Hepatol. 2017 Feb 17. pii: S0168-8278(17)30105.
    PubMed     Text format     Abstract available


  108. YAN Z, Zeng J, Yu Y, Xiang K, et al
    HBVcircle: a Novel Tool to Investigate Hepatitis B Virus Covalently Closed Circular DNA.
    J Hepatol. 2017 Feb 14. pii: S0168-8278(17)30072.
    PubMed     Text format     Abstract available


  109. OLIVIERO B, Mantovani S, Varchetta S, Mele D, et al
    Hepatitis C virus-Induced NK Cell Activation Causes Metzincin-Mediated CD16 Cleavage and Impaired Antibody-Dependent Cytotoxicity.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30069.
    PubMed     Text format     Abstract available


  110. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    PubMed     Text format     Abstract available


  111. ZENG QL, Xu GH, Zhang JY, Li W, et al
    Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30060.
    PubMed     Text format     Abstract available


  112. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Real-world treatment for chronic hepatitis C infection in Germany. Analyses from drug prescription data, 2010 - 2015.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30059.
    PubMed     Text format     Abstract available


  113. CALLEJA JL, Crespo J, Rincon D, Ruiz-Antoran B, et al
    Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real world cohort.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30063.
    PubMed     Text format     Abstract available


  114. GREBELY J, Swan T, Hickman M, Bruneau J, et al
    Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30054.
    PubMed     Text format    


  115. PAWLOTSKY JM
    Consistent advice for people who inject drugs in the 2016 EASL Recommendations on treatment of hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30055.
    PubMed     Text format    


  116. ATKINSON SR, Way MJ, McQuillin A, Morgan MY, et al
    Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30051.
    PubMed     Text format     Abstract available


  117. PRENNER S, VanWagner LB, Flamm SL, Salem R, et al
    Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy with Direct-Acting Antivirals.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30053.
    PubMed     Text format     Abstract available


    January 2017
  118. FARQUHAR MJ, Humphreys IS, Rudge SA, Wilson GK, et al
    Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    J Hepatol. 2017 Jan 23. pii: S0168-8278(17)30013.
    PubMed     Text format     Abstract available


  119. ZEUZEM S, Mizokami M, Pianko S, Mangia A, et al
    NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus: Prevalence and Effect on Treatment Outcome.
    J Hepatol. 2017 Jan 17. pii: S0168-8278(17)30011.
    PubMed     Text format     Abstract available


  120. FILLIOL A, Piquet-Pellorce C, Raguenes-Nicol C, Dion S, et al
    RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis.
    J Hepatol. 2017 Jan 11. pii: S0168-8278(17)30009.
    PubMed     Text format     Abstract available


  121. KLAG T, Dietz J, Werner CR, Schwarz JM, et al
    Hepatitis C "true" late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30006.
    PubMed     Text format    


    December 2016
  122. LEBOSSE F, Testoni B, Fresquet J, Facchetti F, et al
    Intrahepatic innate immune response pathways are down-regulated in untreated chronic hepatitis B.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30757.
    PubMed     Text format     Abstract available


  123. LANGHANS B, Dieter Nischalke H, Kramer B, Hausen A, et al
    Increased peripheral cd4+ regulatory t cells persist after successful direct-acting antiviral treatment of chronic hepatitis C.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30752.
    PubMed     Text format     Abstract available


  124. FERNANDEZ I, Munoz-Gomez R, Pascasio JM, Baliellas C, et al
    Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis c.
    J Hepatol. 2016 Dec 27. pii: S0168-8278(16)30753.
    PubMed     Text format     Abstract available


  125. VUKOTIC R, Conti F, Andreone P
    Hepatitis C virus eradication in elderly: The challenge worth a long-life elixir?
    J Hepatol. 2016 Dec 21. pii: S0168-8278(16)30745.
    PubMed     Text format    


  126. VERRIER ER, Schuster C, Baumert TF
    Advancing hepatitis B virus entry inhibitors.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30706.
    PubMed     Text format    


  127. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    PubMed     Text format     Abstract available


  128. NI Y, Urban S
    Stem cell-derived hepatocytes: a promising novel tool to study Hepatitis B Virus infection.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30704.
    PubMed     Text format    


  129. WYLES D, Dvory-Sobol H, Svarovskaia Doehle ES, Martin R, et al
    Post-Treatment Resistance Analysis of Hepatitis C Virus from Phase 2 and 3 Clinical Trials of Ledipasvir/ Sofosbuvir.
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30699.
    PubMed     Text format     Abstract available


    November 2016
  130. PISCHKE S, Hartl J, Pas SD, Lohse AW, et al
    Hepatitis E virus infection beyond the liver?
    J Hepatol. 2016 Nov 29. pii: S0168-8278(16)30692.
    PubMed     Text format     Abstract available


  131. ZIEMER M, Koukoulioti E, Beyer S, Simon JC, et al
    Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids.
    J Hepatol. 2016 Nov 28. pii: S0168-8278(16)30691.
    PubMed     Text format    


  132. NOTARPAOLO A, Layese R, Magistri P, Gambato M, et al
    Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    J Hepatol. 2016 Nov 26. pii: S0168-8278(16)30688.
    PubMed     Text format     Abstract available


  133. TOYODA H, Kumada T, Tada T, Shimada N, et al
    Efficacy and Tolerability of an IFN-free Regimen with DCV/ASV for Elderly Patients Infected with HCV Genotype 1B.
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30686.
    PubMed     Text format     Abstract available


  134. SHIMURA S, Watashi K, Fukano K, Peel M, et al
    Cyclosporin derivatives inhibit hepatitis B virus entry without interfering the NTCP transporter.
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30683.
    PubMed     Text format     Abstract available


  135. HELLARD M, Pedrana A, Scott N
    Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination?
    J Hepatol. 2016 Nov 21. pii: S0168-8278(16)30680.
    PubMed     Text format    


  136. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed     Text format    


  137. MALLET V, Hamed K, Schwarzinger M
    Prognosis of Patients with Chronic Hepatitis B in France (2008-2013): A Nationwide, Observational and Hospital-based Study.
    J Hepatol. 2016 Nov 5. pii: S0168-8278(16)30642.
    PubMed     Text format     Abstract available


  138. WANG J, Du M, Huang H, Chen R, et al
    Consistent loss of serum HBV RNA might predict the "para-functional cure" of chronic hepatitis B.
    J Hepatol. 2016 Nov 5. pii: S0168-8278(16)30645.
    PubMed     Text format    


  139. JANJUA NZ, Chong M, Kuo M, Woods R, et al
    Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    J Hepatol. 2016 Nov 3. pii: S0168-8278(16)30637.
    PubMed     Text format     Abstract available


  140. FALADE-NWULIA O, Sulkowski M
    The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection.
    J Hepatol. 2016 Nov 2. pii: S0168-8278(16)30636.
    PubMed     Text format    


    October 2016
  141. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    PubMed     Text format     Abstract available


  142. LEMOINE M, Thursz MR
    Field battle against hepatitis B infection and HCC in Africa.
    J Hepatol. 2016 Oct 19. pii: S0168-8278(16)30578.
    PubMed     Text format     Abstract available


  143. BEGUELIN C, Moradpour D, Sahli R, Suter-Riniker F, et al
    Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.
    J Hepatol. 2016 Oct 13. pii: S0168-8278(16)30569.
    PubMed     Text format     Abstract available


  144. XIA Y, Carpentier A, Cheng X, Block PD, et al
    Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions.
    J Hepatol. 2016 Oct 13. pii: S0168-8278(16)30572.
    PubMed     Text format     Abstract available


  145. DEUFFIC-BURBAN S, Boursier J, Leroy V, Yazdanpanah Y, et al
    Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
    J Hepatol. 2016 Oct 12. pii: S0168-8278(16)30568.
    PubMed     Text format     Abstract available


  146. ROSS DB, Belperio PS, Chartier M, Backus LI, et al
    Hepatitis C Testing in U.S. Veterans Born 1945-1965: An Update.
    J Hepatol. 2016 Oct 5. pii: S0168-8278(16)30557.
    PubMed     Text format    


  147. JUSTICE AC, Esserman D, Sarkar S, Levin FL, et al
    Reply to: "Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965".
    J Hepatol. 2016 Oct 4. pii: S0168-8278(16)30558.
    PubMed     Text format    


  148. VAN DER MEER AJ, Berenguer M
    Reversion of disease manifestations after HCV eradication.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  149. CACOUB P, Desbois AC, Isnard-Bagnis C, Rocatello D, et al
    Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  150. MAASOUMY B, Vermehren J
    Diagnostics in hepatitis C: The end of response-guided therapy?
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  151. EASTERBROOK PJ
    Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  152. MIDGARD H, Weir A, Palmateer N, Lo Re V 3rd, et al
    HCV epidemiology in high-risk groups and the risk of reinfection.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  153. HEIM MH, Bochud PY, George J
    Host - hepatitis C viral interactions: The role of genetics.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  154. BUKH J
    The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  155. MORADPOUR D, Grakoui A, Manns MP
    Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  156. YOUNOSSI ZM, Birerdinc A, Henry L
    Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  157. FORNS X, Berg T
    Hepatitis C virus - A teacher of clinical research, cell biology and immunology.
    J Hepatol. 2016;65.
    PubMed     Text format    


  158. VAN DER VALK M, Zaaijer HL, Kater AP, Schinkel J, et al
    Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.
    J Hepatol. 2016 Oct 1. pii: S0168-8278(16)30541.
    PubMed     Text format    


    September 2016
  159. CHAYANUPATKUL M, Omino R, Mittal S, Kramer JR, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2016 Sep 28. pii: S0168-8278(16)30540.
    PubMed     Text format     Abstract available


  160. INGILIZ P, Martin TC, Rodger A, Stellbrink HJ, et al
    HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.
    J Hepatol. 2016 Sep 17. pii: S0168-8278(16)30505.
    PubMed     Text format     Abstract available


  161. XIANG KH, Michailidis E, Ding H, Peng YQ, et al
    Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA.
    J Hepatol. 2016 Sep 17. pii: S0168-8278(16)30506.
    PubMed     Text format     Abstract available


  162. LAI CL, Wong D, Ip P, Kopaniszen M, et al
    Reduction of Covalently Closed Circular DNA with Long-term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B.
    J Hepatol. 2016 Sep 14. pii: S0168-8278(16)30487.
    PubMed     Text format     Abstract available



  163. EASL Recommendations on Treatment of Hepatitis C 2016.
    J Hepatol. 2016 Sep 12. pii: S0168-8278(16)30489.
    PubMed     Text format    


  164. POL S, Bourliere M, Lucier S, Hezode C, et al
    Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    J Hepatol. 2016 Sep 10. pii: S0168-8278(16)30486.
    PubMed     Text format     Abstract available


  165. WANG H, Tai AW
    Continuous de novo generation of spatially segregated hepatitis C virus replication organelles revealed by pulse-chase imaging.
    J Hepatol. 2016 Sep 3. pii: S0168-8278(16)30483.
    PubMed     Text format     Abstract available


  166. RIZZETTO M, Niro GA
    Myrcludex B, a novel therapy for chronic hepatitis D?
    J Hepatol. 2016;65:465-6.
    PubMed     Text format    


    August 2016
  167. ZAVAGLIA C, Okolicsanji S, Cesarini L, Mazzarelli C, et al
    Is the risk of neoplastic recurrence increased after prescribing Direct Acting Antivirals for HCV patients whose HCC was previously cured?
    J Hepatol. 2016 Aug 31. pii: S0168-8278(16)30481.
    PubMed     Text format    


  168. CORNBERG M, Wong VW, Locarnini S, Brunetto M, et al
    The role of quantitative hepatitis b surface antigen revisited.
    J Hepatol. 2016 Aug 26. pii: S0168-8278(16)30441.
    PubMed     Text format     Abstract available


  169. WAZIRY R, Grebely J, Amin J, Alavi M, et al
    Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).
    J Hepatol. 2016 Aug 25. pii: S0168-8278(16)30442.
    PubMed     Text format     Abstract available


  170. FUNG S, Kwan P, Fabri M, Horban A, et al
    Tenofovir disoproxil fumarate (TDF) versus TDF/emtricitabine (FTC) in lamivudine-resistant hepatitis B: a 5-year randomized study.
    J Hepatol. 2016 Aug 18. pii: S0168-8278(16)30440.
    PubMed     Text format     Abstract available


  171. INNES H, McDonald S, Hayes P, Dillon JF, et al
    Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.
    J Hepatol. 2016 Aug 18. pii: S0168-8278(16)30428.
    PubMed     Text format     Abstract available


  172. HEDEGAARD DL, Tully DC, Rowe IA, Reynolds GM, et al
    High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease.
    J Hepatol. 2016 Aug 13. pii: S0168-8278(16)30424.
    PubMed     Text format     Abstract available


  173. MINAMI T, Tateishi R, Nakagomi R, Fujiwara N, et al
    The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.
    J Hepatol. 2016 Aug 11. pii: S0168-8278(16)30419.
    PubMed     Text format    


  174. ROBAEYS G, Rob B, Azar DG, Razavi H, et al
    Global genotype distribution of hepatitis C viral infection among people who inject drugs.
    J Hepatol. 2016 Aug 9. pii: S0168-8278(16)30418.
    PubMed     Text format     Abstract available


  175. EBERHARD JM, Kummer S, Hartjen P, Hufner A, et al
    Reduced CD161+MAIT cell frequencies in HCV and HIV/HCV co-infection. Is the liver the heart of the matter?
    J Hepatol. 2016 Aug 1. pii: S0168-8278(16)30401.
    PubMed     Text format     Abstract available


    July 2016
  176. CARDOSO H, Vale AM, Rodrigues S, Goncalves R, et al
    High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30397.
    PubMed     Text format    


  177. ZENG QL, Li ZQ, Liang HX, Xu GH, et al
    Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30399.
    PubMed     Text format    


  178. VIONNET J, Saouli AC, Pascual M, Stucker F, et al
    Therapeutic Drug Monitoring for Sofosbuvir and Daclatasvir in Transplant Recipients with Chronic Hepatitis C and Advanced Renal Disease.
    J Hepatol. 2016 Jul 25. pii: S0168-8278(16)30347.
    PubMed     Text format    


  179. DEGASPERI E, De Nicola S, Rumi M, D'Ambrosio R, et al
    HCV-RNA Kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30344.
    PubMed     Text format    


  180. DESNOYER A, Le MP, Yazdanpanah Y, Peytavin G, et al
    Reply to: "Therapeutic Drug Monitoring for Sofosbuvir and Daclatasvir in Transplant Recipients with Chronic Hepatitis C and Advanced Renal Disease".
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30345.
    PubMed     Text format    


  181. MAASOUMY B, Vermehren J, Wedemeyer H, Sarrazin C, et al
    Clinical value of on-treatment HCV-RNA levels during treatment with sofosbuvir and ribavirin in genotype 3 patients.
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30343.
    PubMed     Text format    


  182. YAMASHITA T, Nault JC
    Stemness of liver cancer: from hepatitis B virus to Wnt activation.
    J Hepatol. 2016 Jul 19. pii: S0168-8278(16)30338.
    PubMed     Text format    


  183. LI TC, Zhou X, Yoshizaki S, Ami Y, et al
    Production of Infectious Dromedary Camel Hepatitis E Virus by a Reverse Genetic System: Potential for Zoonotic Infection.
    J Hepatol. 2016 Jul 19. pii: S0168-8278(16)30337.
    PubMed     Text format     Abstract available



  184. Joint society statement for the elimination of viral hepatitis.
    J Hepatol. 2016 Jul 15. pii: S0168-8278(16)30339.
    PubMed     Text format    


  185. ALAVI M, Law MG, Grebely J, Amin J, et al
    Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012.
    J Hepatol. 2016 Jul 8. pii: S0168-8278(16)30321.
    PubMed     Text format     Abstract available


  186. YANG JD, Aqel BA, Pungpapong S, Gores GJ, et al
    Direct Acting Antiviral Therapy and Tumor Recurrence after Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.
    J Hepatol. 2016 Jul 5. pii: S0168-8278(16)30318.
    PubMed     Text format    


  187. CHEUNG MC, Walker AJ, Hudson BE, Verma S, et al
    Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30314.
    PubMed     Text format     Abstract available


    June 2016
  188. CONTI F, Buonfiglioli F, Scuteri A, Crespi C, et al
    Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals.
    J Hepatol. 2016 Jun 24. pii: S0168-8278(16)30303.
    PubMed     Text format     Abstract available


  189. FUNG J, Seto WK, Lai CL, Yuen J, et al
    Corrigendum to "Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy" [J Hepatol 2011;54:195-200].
    J Hepatol. 2016;64:1460.
    PubMed     Text format    


  190. COILLY A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, et al
    Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation - The CO23 ANRS CUPILT study.
    J Hepatol. 2016 Jun 1. pii: S0168-8278(16)30253.
    PubMed     Text format     Abstract available


    May 2016
  191. WANG J, Shen T, Huang X, Renuka Kumar G, et al
    Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.
    J Hepatol. 2016 May 28. pii: S0168-8278(16)30241.
    PubMed     Text format     Abstract available


  192. MANDORFER M, Kozbial K, Schwabl P, Freissmuth C, et al
    Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30238.
    PubMed     Text format     Abstract available


  193. MANI SK, Zhang H, Diab A, Pascuzzi PE, et al
    EpCAM-Regulated Intramembrane Proteolysis Induces a Cancer Stem Cell-like Gene Signature in Hepatitis B Virus-infected Hepatocytes.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30208.
    PubMed     Text format     Abstract available


  194. HARTL J, Denzer U, Ehlken H, Zenouzi R, et al
    Validation of transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30209.
    PubMed     Text format     Abstract available


  195. SUN J, Ma H, Xie Q, Xie Y, et al
    Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30210.
    PubMed     Text format     Abstract available


  196. TSENG A, Wong DK
    Hepatotoxicity and Potential Drug Interaction with Ledipasvir/Sofosbuvir In HIV/HCV Infected Patients.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30201.
    PubMed     Text format     Abstract available


  197. LOK AS, Pan CQ, Han SB, Trinh HN, et al
    Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30202.
    PubMed     Text format     Abstract available


  198. VANDENBULCKE H, Moreno C, Colle I, Knebel JF, et al
    Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis: a prospective study.
    J Hepatol. 2016 May 12. pii: S0168-8278(16)30184.
    PubMed     Text format     Abstract available


  199. DEBING Y, Ramiere C, Dallmeier K, Piorkowski G, et al
    Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity.
    J Hepatol. 2016 May 9. pii: S0168-8278(16)30187.
    PubMed     Text format     Abstract available


  200. BULTEEL N, Sarathy PP, Forrest E, Stanley AJ, et al
    Factors Associated with Spontaneous Clearance of Chronic Hepatitis c Virus Infection: a Retrospective Case Control Study.
    J Hepatol. 2016 May 4. pii: S0168-8278(16)30182.
    PubMed     Text format     Abstract available


  201. MOENNE-LOCCOZ R, Severac F, Baumert TF, Habersetzer F, et al
    Usefulness of corticosteroids as first-line therapy in patients with acute severe autoimmune hepatitis.
    J Hepatol. 2016 May 4. pii: S0168-8278(16)30183.
    PubMed     Text format    


  202. COLOMBO M
    EASL Recognition Award Recipient 2016: Prof. Antonio Craxi.
    J Hepatol. 2016;64:1001-2.
    PubMed     Text format    


  203. PADEGIMAS A, Forde KA, Goldberg LR, Birati EY, et al
    Myo-pericarditis secondary to ledipasvir-sofosbuvir therapy.
    J Hepatol. 2016;64:1196-8.
    PubMed     Text format    


    April 2016
  204. BLANK A, Markert C, Hohmann N, Carls A, et al
    Myrcludex B: a first-in-human clinical study with a first-in-class hepatitis B and hepatitis D virus entry inhibitor.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30145.
    PubMed     Text format     Abstract available


  205. BOGOMOLOV P, Alexandrov A, Voronkova N, Macievich M, et al
    Interim results of a Phase Ib/IIa study of the entry inhibitor myrcludex B in chronic hepatitis D infected patients.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30148.
    PubMed     Text format     Abstract available


  206. FOSTER G
    Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme".
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30142.
    PubMed     Text format    


  207. GRAY E, O'Leary A, Stewart S, Bergin C, et al
    High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30143.
    PubMed     Text format    


  208. SARKAR S, Esserman DA, Skanderson M, Levin FL, et al
    Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965.
    J Hepatol. 2016 Apr 26. pii: S0168-8278(16)30144.
    PubMed     Text format     Abstract available


  209. MAASOUMY B, Vermehren J, Welker MW, Bremer B, et al
    Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens.
    J Hepatol. 2016 Apr 13. pii: S0168-8278(16)30108.
    PubMed     Text format     Abstract available


  210. REIG M, Marino Z, Perello C, Inarrairaegui M, et al
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution.
    J Hepatol. 2016 Apr 12. pii: S0168-8278(16)30113.
    PubMed     Text format     Abstract available


  211. BHAMIDIMARRI KR, Martin P
    Finally safe and effective treatment options for hepatitis C in hemodialysis patients.
    J Hepatol. 2016 Apr 9. pii: S0168-8278(16)30105.
    PubMed     Text format    


  212. LUNEMANN S, Martrus G, Holzemer A, Chapel A, et al
    Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C03:04 and modulate NK cell function.
    J Hepatol. 2016 Apr 4. pii: S0168-8278(16)30097.
    PubMed     Text format     Abstract available


  213. MEHTA SH, Thomas DL
    Doing the math on hepatitis C virus treatment.
    J Hepatol. 2016 Apr 2. pii: S0168-8278(16)30096.
    PubMed     Text format    


  214. BLONDOT ML, Bruss V, Kann M
    Intracellular transport and egress of hepatitis B virus.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  215. LUCIFORA J, Protzer U
    Attacking hepatitis B virus cccDNA - The holy grail to hepatitis B cure.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  216. TONG S, Revill P
    Overview of hepatitis B viral replication and genetic variability.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  217. LI W, Urban S
    Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  218. ALLWEISS L, Dandri M
    Experimental in vitro and in vivo models for the study of human hepatitis B virus infection.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  219. DURANTEL D, Zoulim F
    New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  220. SUREAU C, Negro F
    The hepatitis delta virus: Replication and pathogenesis.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  221. DUBUQUOY L
    Lipocalin 2 highlights the complex role of neutrophils in alcoholic liver disease.
    J Hepatol. 2016;64:770-2.
    PubMed     Text format    


  222. LEVRERO M, Zucman-Rossi J
    Mechanisms of HBV-induced hepatocellular carcinoma.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  223. BERTOLETTI A, Ferrari C
    Adaptive immunity in HBV infection.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  224. MAINI MK, Gehring AJ
    The role of innate immunity in the immunopathology and treatment of HBV infection.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  225. SEEGER C, Mason WS
    HBV replication, pathobiology and therapy: Unanswered questions.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  226. ROBERT O, Boujedidi H, Bigorgne A, Ferrere G, et al
    Decreased expression of the glucocorticoid receptor-GILZ pathway in Kupffer cells promotes liver inflammation in obese mice.
    J Hepatol. 2016;64:916-24.
    PubMed     Text format     Abstract available


    March 2016
  227. BRUNO S, Di Marco V, Iavarone M, Roffi L, et al
    Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
    J Hepatol. 2016 Mar 23. pii: S0168-8278(16)00075.
    PubMed     Text format     Abstract available


  228. DEBING Y, Moradpour D, Neyts J, Gouttenoire J, et al
    Update on Hepatitis E Virology:Implications for Clinical Practice.
    J Hepatol. 2016 Mar 7. pii: S0168-8278(16)30011.
    PubMed     Text format     Abstract available


  229. YOUNOSSI ZM, Stepanova M, Feld J, Zeuzem S, et al
    Sofosbuvir/Velpatasvir Improves Patient-Reported Outcomes in HCV Patients: Results from ASTRAL-1 Placebo-Controlled Trial.
    J Hepatol. 2016 Mar 5. pii: S0168-8278(16)30008.
    PubMed     Text format     Abstract available


  230. DESNOYER A, Pospai D, Le MP, Gervais A, et al
    Sofosbuvir-containing regimen for HCV infection in hemodialysis patients: 400 mg daily or only on the day of hemodialysis.
    J Hepatol. 2016 Mar 4. pii: S0168-8278(16)30010.
    PubMed     Text format     Abstract available


  231. YAMAMOTO N, Sato Y, Munakata T, Kakuni M, et al
    Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection.
    J Hepatol. 2016;64:547-55.
    PubMed     Text format     Abstract available


    February 2016
  232. VO M, Holz LE, Wong YC, English K, et al
    The extent and duration of acute hepatitis in mice is dominated by the function rather than by the survival of effector CD8 T cells.
    J Hepatol. 2016 Feb 25. pii: S0168-8278(16)00160.
    PubMed     Text format     Abstract available


  233. JACKA B, Applegate T, Poon AF, Raghwani J, et al
    Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.
    J Hepatol. 2016 Feb 25. pii: S0168-8278(16)00165.
    PubMed     Text format     Abstract available


  234. ZAHND C, Salazar-Vizcaya L, Dufour JF, Mullhaupt B, et al
    Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men.
    J Hepatol. 2016 Feb 24. pii: S0168-8278(16)00164.
    PubMed     Text format     Abstract available


  235. MOSTAFA A, Shimakawa Y, Medhat A, Mikhail NN, et al
    Excess mortality rate associated with hepatitis C virus infection: a community-based cohort study in rural Egypt.
    J Hepatol. 2016 Feb 24. pii: S0168-8278(16)00167.
    PubMed     Text format     Abstract available


  236. OZASLAN E, Efe C
    Further considerations in autoimmune hepatitis.
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00154.
    PubMed     Text format    


  237. LOHSE AW, Chazouilleres O, Dalekos G, Drenth J, et al
    Clinical Practise Guidelines Autoimmune Hepatitis: Further considerations.
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00159.
    PubMed     Text format    


  238. DAHARI H, Canini L, Graw F, Uprichard SL, et al
    HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
    J Hepatol. 2016 Feb 20. pii: S0168-8278(16)00153.
    PubMed     Text format     Abstract available


  239. GOUTTENOIRE J, Moradpour D
    A Mouse Model for Hepatitis E Virus Infection.
    J Hepatol. 2016 Feb 15. pii: S0168-8278(16)00122.
    PubMed     Text format    


  240. STEVEN FOX D, McCombs JS
    Optimizing HCV Treatment - Moving Beyond the Cost Conundrum.
    J Hepatol. 2016 Feb 11. pii: S0168-8278(16)00089.
    PubMed     Text format    


  241. GENG Y, Zhao C, Wang Y
    Reply to "Rhesus macaques persistently infected with hepatitis E shed virus into urine".
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00085.
    PubMed     Text format    


  242. MARTIN NK, Vickerman P, Dore GJ, Grebely J, et al
    How should HCV treatment be prioritized in the direct-acting antiviral era? An economic evaluation including population prevention benefits.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00086.
    PubMed     Text format     Abstract available


  243. HUANG F, Yang C, Zhou X, Yu W, et al
    Rhesus macaques persistently infected with hepatitis E shed virus into urine.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00082.
    PubMed     Text format    


  244. ESLAM M, Hashem AM, Romero-Gomez M, Berg T, et al
    FibroGENE: A gene-based model for staging liver fibrosis.
    J Hepatol. 2016;64:390-8.
    PubMed     Text format     Abstract available


  245. PAVLIDES M, Banerjee R, Sellwood J, Kelly CJ, et al
    Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.
    J Hepatol. 2016;64:308-15.
    PubMed     Text format     Abstract available


    January 2016
  246. FOSTER GR, Irving WL, Cheung MC, Walker AJ, et al
    Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jan 29. pii: S0168-8278(16)00065.
    PubMed     Text format     Abstract available


  247. WEBB G, Chen YY, Li KK, Neil D, et al
    Single-gene association between GATA-2 and autoimmune hepatitis: a novel genetic insight highlighting immunologic pathways to disease.
    J Hepatol. 2016 Jan 23. pii: S0168-8278(16)00051.
    PubMed     Text format     Abstract available


  248. UDOMPAP P, Mannalithara A, Heo N, Kim D, et al
    Increasing Prevalence of Cirrhosis among US Adults Aware or Unaware of their Chronic Hepatitis C Virus Infection.
    J Hepatol. 2016 Jan 22. pii: S0168-8278(16)00014.
    PubMed     Text format     Abstract available


  249. ALLWEISS L, Gass S, Giersch K, Groth A, et al
    Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation.
    J Hepatol. 2016 Jan 21. pii: S0168-8278(16)00017.
    PubMed     Text format     Abstract available


  250. YANG YH, Chen WC, Tsai YH, Chen PC, et al
    Reply to "Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection".
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00011.
    PubMed     Text format    


  251. HOOFNAGLE JH
    Hepatic Decompensation during Direct-Acting Antiviral Therapy of Chronic Hepatitis C.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00010.
    PubMed     Text format    


  252. YU ML
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00012.
    PubMed     Text format    


  253. MIDGARD H, Bjoro B, Maeland A, Konopski Z, et al
    Hepatitis C Reinfection Following Sustained Virological Response - Seven-Year Follow-Up Of Patients Infected Through Injecting Drug Use.
    J Hepatol. 2016 Jan 9. pii: S0168-8278(16)00003.
    PubMed     Text format     Abstract available


  254. BAUMERT TF, Schuster C, Cosset FL, Dubuisson J, et al
    Addressing the Next Challenges: a Summary of the 22nd International Symposium on Hepatitis C Virus and Related Viruses.
    J Hepatol. 2016 Jan 9. pii: S0168-8278(16)00004.
    PubMed     Text format     Abstract available


  255. YOUNOSSI ZM, Stepanova M, Estep M, Negro F, et al
    Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    J Hepatol. 2016;64:29-36.
    PubMed     Text format     Abstract available


    December 2015
  256. CHAN HL, Ahn SH, Chang TT, Peng CY, et al
    Peginterferon Lambda for the Treatment of HBeAg-Positive Chronic Hepatitis B: A Randomized Phase 2b Study (LIRA-B).
    J Hepatol. 2015 Dec 28. pii: S0168-8278(15)00859.
    PubMed     Text format     Abstract available


  257. HULLEGIE SJ, Claassen MA, van den Berk GE, van der Meer JT, et al
    A 12-Week Treatment with Boceprevir, Peginterferon and Ribavirin for Acute Hepatitis C in HIV infected patients.
    J Hepatol. 2015 Dec 12. pii: S0168-8278(15)00805.
    PubMed     Text format     Abstract available


  258. MARCHAN-LOPEZ A, Dominguez-Dominguez L, Kessler-Saiz P, Jarrin-Estupinan ME, et al
    Liver Failure in Human Immunodeficiency Virus - Hepatitis C Virus Coinfection Treated with Sofosbuvir, Ledipasvir and Antiretroviral Therapy.
    J Hepatol. 2015 Dec 9. pii: S0168-8278(15)00799.
    PubMed     Text format    


  259. DYSON JK, McPherson S
    Reply to "Liver Failure in Human Immunodeficiency Virus - Hepatitis C Virus Coinfection Treated with Sofosbuvir, Ledipasvir and Antiretroviral Therapy".
    J Hepatol. 2015 Dec 9. pii: S0168-8278(15)00800.
    PubMed     Text format    


  260. PAPATHEODORIDIS G, Dalekos G, Sypsa V, Yurdaydin C, et al
    Page-B: Risk Score for Hepatocellular Carcinoma in Caucasians with Chronic Hepatitis B Under 5-Year Entecavir or Tenofovir Therapy.
    J Hepatol. 2015 Dec 8. pii: S0168-8278(15)00795.
    PubMed     Text format     Abstract available


    November 2015
  261. WELKER MW, Luhne S, Lange CM, Vermehren J, et al
    Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00792.
    PubMed     Text format     Abstract available


  262. BILLIOUD G, Kruse RL, Carrillo M, Whitten-Bauer C, et al
    In vivo Reduction of Hepatitis B Virus Antigenemia and Viremia by Antisense Oligonucleotides.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00790.
    PubMed     Text format     Abstract available


  263. RAY KIM W, Berg T, Asselah T, Flisiak R, et al
    Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00770.
    PubMed     Text format     Abstract available


  264. HELSEN N, Debing Y, Paeshuyse J, Dallmeier K, et al
    Stem cell-derived hepatocytes: a novel model for hepatitis E virus replication.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00771.
    PubMed     Text format     Abstract available


  265. LEMPP FA, Mutz P, Lipps C, Wirth D, et al
    Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor.
    J Hepatol. 2015 Nov 11. pii: S0168-8278(15)00736.
    PubMed     Text format     Abstract available


    September 2015
  266. YAN M, Ha J, Aguilar M, Bhuket T, et al
    Birth Cohort-Specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis, Treatment, and Long-term Survival.
    J Hepatol. 2015 Sep 16. pii: S0168-8278(15)00623.
    PubMed     Text format     Abstract available


  267. KHATRI A, Menon R
    Reply to comments on: Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Sep 5. pii: S0168-8278(15)00612.
    PubMed     Text format    


  268. CHTIOUI H, Buclin T
    Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Sep 4. pii: S0168-8278(15)00610.
    PubMed     Text format    


    August 2015
  269. GRANCINI V, Trombetta M, Lunati ME, Zimbalatti D, et al
    Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00553.
    PubMed     Text format     Abstract available


  270. HUNG GY, Horng JL, Yen HJ, Lee CY, et al
    Changing Incidence Patterns of Hepatocellular Carcinoma Among Age Groups in Taiwan.
    J Hepatol. 2015 Aug 6. pii: S0168-8278(15)00534.
    PubMed     Text format     Abstract available


    June 2015
  271. LAMPERTICO P, Invernizzi F, Vigano M, Loglio A, et al
    The long-term benefits of nucleos(t)ide analogs on esophageal varices in compensated HBV cirrhotics with no or small esophageal varices: A 12-year prospective cohort study.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00397.
    PubMed     Text format     Abstract available


  272. ALMISHRI W, Deans J, Swain MG
    Rapid activation and hepatic recruitment of innate-like regulatory B cells after invariant NKT cell stimulation in mice.
    J Hepatol. 2015 Jun 18. pii: S0168-8278(15)00398.
    PubMed     Text format     Abstract available


  273. KHATRI A, Menon R, Marbury TC, Lawitz E, et al
    Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Jun 10. pii: S0168-8278(15)00387.
    PubMed     Text format     Abstract available


    April 2015
  274. PAWLIK TM, Soubrane O
    Metabolic syndrome-associated hepatocellular carcinoma: questions still unanswered.
    J Hepatol. 2015 Apr 7. pii: S0168-8278(15)00245.
    PubMed     Text format    


  275. PEIFFER KH, Akhras S, Himmelsbach K, Hassemer M, et al
    Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level.
    J Hepatol. 2015;62:791-8.
    PubMed     Text format     Abstract available


  276. MATHURIN P, Bataller R
    Trends in the management and burden of alcoholic liver disease.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  277. ARROYO V, Moreau R, Jalan R, Gines P, et al
    Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


    January 2015
  278. NEGRO F
    Are statins a remedy for all seasons?
    J Hepatol. 2015;62:8-10.
    PubMed     Text format    


    December 2014
  279. SOHN W, Paik YH, Cho JY, Lim HY, et al
    Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
    J Hepatol. 2014 Dec 13. pii: S0168-8278(14)00927.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: